Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction

Physiologically‐based pharmacokinetic (PBPK) modeling is a powerful tool to quantitatively describe drug disposition profiles in vivo, thereby providing an alternative to predict drug–drug interactions (DDIs) that have not been tested clinically. This study aimed to predict effects of rifampin‐media...

Full description

Bibliographic Details
Main Authors:	Shinji Yamazaki, Chester Costales, Sarah Lazzaro, Soraya Eatemadpour, Emi Kimoto, Manthena V. Varma
Format:	Article
Language:	English
Published:	Wiley 2019-09-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.12458

Similar Items

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling
by: Chester Costales, et al.
Published: (2021-09-01)

Corrigendum to: Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
by: Shinji Yamazaki, et al.
Published: (2022-10-01)

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients
by: Levin Thomas, et al.
Published: (2020-06-01)

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates
by: Xian Pan, et al.
Published: (2021-12-01)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
by: Rui-juan Xu, et al.
Published: (2021-07-01)

Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney
by: Ryuta Asaumi, et al.
Published: (2022-07-01)

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
by: Bettina Gerner, et al.
Published: (2021-05-01)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
by: Shinji Yamazaki, et al.
Published: (2023-01-01)

Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis
by: Valéria G. F. Pinheiro, et al.

Etymologia: Rifampin
by: Ronnie Henry
Published: (2018-03-01)

Potential Pharmacokinetic Effect of Chicken Xenobiotic Receptor Activator on Sulfadiazine: Involvement of P-glycoprotein Induction
by: Mei Li, et al.
Published: (2022-07-01)

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis
by: McIlleron Helen, et al.
Published: (2009-04-01)

Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers.
by: Mengjie Guo, et al.
Published: (2013-01-01)

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis
by: Mônica C. Façanha, et al.

Rifampin-resistant Meningococcal Disease
by: Jean Rainbow, et al.
Published: (2005-06-01)

Rifampin-resistant Neisseria meningitidis
by: Muhamed-Kheir Taha, et al.
Published: (2006-05-01)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
by: Shinji Nakayama, et al.
Published: (2023-10-01)

Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis
by: Rasoul Mirzaei, et al.
Published: (2022-06-01)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
by: Vidya Perera, et al.
Published: (2022-12-01)

Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance
by: Ali Darwich, et al.
Published: (2021-09-01)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
by: Huang YT, et al.
Published: (2018-08-01)

Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics
by: Rajinder Bhardwaj, et al.
Published: (2024-12-01)

Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin
by: Nicolas Hohmann, et al.
Published: (2024-08-01)

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
by: Ameeta S. Kalokhe, et al.
Published: (2012-03-01)

Deranged Haemostasis: Rifampin-Induced Coagulopathy
by: Raghu Tiperneni, et al.
Published: (2022-05-01)

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan
by: Pierre‐Eric Juif, et al.
Published: (2019-09-01)

A therapeutic study comparing the association of rifampin, ofloxacin and minocycline with the association of rifampin, clofazimine and dapsone in multibacillary leprosy patients
by: Ura Somei
Published: (2007-01-01)

Antimalarial effects of rifampin in Plasmodium vivax malaria.
by: Pukrittayakamee, S, et al.
Published: (1994)

Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin
by: Pengfei She, et al.
Published: (2022-12-01)

Rifampin phosphotransferase is an unusual antibiotic resistance kinase
by: Peter J. Stogios, et al.
Published: (2016-04-01)

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
by: I-Ching Sam, et al.
Published: (2006-05-01)

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
by: Hengbang Wang, et al.
Published: (2024-09-01)

Pharmacokinetic interactions: The effects of selected herbal extracts on permeation of P-glycoprotein substrate drugs across excised pig intestinal tissue
by: Bianca Peterson, et al.
Published: (2022-01-01)

Rifampin Resistant Tuberculosis; Factors and Demo- Graphic Features
by: Huda Sarwar, et al.
Published: (2024-09-01)

Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?
by: Nora Renz, et al.
Published: (2021-02-01)

Rifampin resistance and its fitness cost in Riemerella anatipestifer
by: Jiakai Sun, et al.
Published: (2019-05-01)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
by: Elsje Pienaar, et al.
Published: (2018-01-01)

Drug Resistance in Mycobacterium Tuberculosis Isolates to Isoniazid and Rifampin
by: M Pourhajibagher, et al.
Published: (2012-05-01)

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis
by: Diana B. Pedral-Sampaio, et al.

Efficacy of Co-trimoxazol and Rifampine in treatment of childhood Brucellosis
by: MR Hassanjani Roshan, et al.
Published: (2000-10-01)